Longee D C, Wikstrand C J, Månsson J E, He X, Fuller G N, Bigner S H, Fredman P, Svennerholm L, Bigner D D
Department of Pathology, Duke University Medical Center, Durham, NC 27710.
Acta Neuropathol. 1991;82(1):45-54. doi: 10.1007/BF00310922.
Monoclonal antibodies (mAbs) recognizing the disialoganglioside II3(NeuAc)2GgOse3Cer (GD2) were produced by immunizing mice with the GD2-expressing neuroblastoma cell line LAN-1 and a prefusion boost with purified GD2 coupled to Salmonella minnesota. Two IgM mAbs were isolated which demonstrated high levels of reactivity (binding ratios in excess of 100) with GD2 by solid-phase radioimmunoassay and positivity in high-performance thin-layer chromatography (HPTLC) immunostain; only one (DMAb-20) was subsequently shown by analysis with a panel of defined ganglioside species to be specific for the minimum epitope of GD2 GalNAc beta 1-4(NeuAc alpha 2-8-NeuAc alpha 2-3)Gal-, DMAb-20 was used to evaluate the expression of GD2 by malignant glioma and medulloblastoma cell lines using cell surface radioimmunoassay. indirect membrane immunofluorescence. HPTLC immunostain, and densitometric analysis of extracted gangliosides from selected cell lines. Sixteen of 20 (80%) malignant glioma and 5 of 5 medulloblastoma cell lines reacted with DMAb-20; in agreement with previous studies, 5 of 5 neuroblastoma and 2 of 3 melanoma cell lines also reacted with DMAb-20, GD2 was proportionally increased in the glioma and medulloblastoma cell lines relative to levels in normal brain, as determined by densitometric analysis. In a phenotypic survey of malignant glioma biopsies, tumor cells in 24 of 30 (80%) cases stained positively with DMAb-20. Reactive astrocytes, both within the adjacent to tumors, were frequently intensely stained. Among the morphological variants of glioblastoma examined, the most intense staining with DMAb-20 was observed in neoplastic gemistocytes, with the weakest or absent staining in small cell glioblastomas. As GD2 is a commonly expressed surface antigen of gliomas and medulloblastomas, expression of which is retained in tissue culture. DMAb-20 will be useful in determining the functional role of GD2 in cell-cell interaction, adhesion, and invasion, and in defining altered growth control mechanisms of central nervous system neoplasms in in vitro models.
通过用表达GD2的神经母细胞瘤细胞系LAN-1免疫小鼠,并以与明尼苏达沙门氏菌偶联的纯化GD2进行预融合加强免疫,制备了识别二唾液酸神经节苷脂II3(NeuAc)2GgOse3Cer(GD2)的单克隆抗体(mAb)。分离出两种IgM单克隆抗体,通过固相放射免疫测定法显示它们与GD2具有高水平的反应性(结合率超过100),并且在高效薄层色谱(HPTLC)免疫染色中呈阳性;随后通过一组确定的神经节苷脂种类分析表明,只有一种(DMAb-20)对GD2的最小表位GalNAcβ1-4(NeuAcα2-8-NeuAcα2-3)Gal-具有特异性。DMAb-20用于通过细胞表面放射免疫测定、间接膜免疫荧光、HPTLC免疫染色以及对选定细胞系提取的神经节苷脂进行光密度分析,来评估恶性胶质瘤和髓母细胞瘤细胞系中GD2的表达。20个恶性胶质瘤细胞系中的16个(80%)和5个髓母细胞瘤细胞系中的5个与DMAb-20反应;与先前的研究一致,5个神经母细胞瘤细胞系中的5个和3个黑色素瘤细胞系中的2个也与DMAb-20反应。通过光密度分析确定,相对于正常脑内的水平,GD2在胶质瘤和髓母细胞瘤细胞系中按比例增加。在恶性胶质瘤活检的表型调查中,30例中的24例(80%)肿瘤细胞用DMAb-20染色呈阳性。肿瘤相邻部位的反应性星形胶质细胞经常被强烈染色。在检查的胶质母细胞瘤的形态学变体中,观察到肿瘤性肥胖细胞对DMAb-20的染色最强,而小细胞胶质母细胞瘤的染色最弱或无染色。由于GD2是胶质瘤和髓母细胞瘤常见表达的表面抗原,其表达在组织培养中得以保留,DMAb-20将有助于确定GD2在细胞间相互作用、黏附和侵袭中的功能作用,并有助于在体外模型中界定中枢神经系统肿瘤改变的生长控制机制。